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At least 200 single-nucleotide polymorphisms (SNPs) are asso-
ciated with multiple sclerosis (MS) risk. A key function that could
mediate SNP-encoded MS risk is their regulatory effects on gene
expression. We performed microarrays using RNA extracted from
purified immune cell types from 73 untreated MS cases and 97
healthy controls and then performed Cis expression quantitative
trait loci mapping studies using additive linear models. We de-
scribe MS risk expression quantitative trait loci associations for
129 distinct genes. By extending these models to include an in-
teraction term between genotype and phenotype, we identify MS
risk SNPs with opposing effects on gene expression in cases
compared with controls, namely, rs2256814 MYT1 in CD4 cells (q =
0.05) and rs12087340 RF00136 in monocyte cells (q = 0.04). The
rs703842 SNPwas also associated with a differential effect size on
the expression of the METTL21B gene in CD8 cells of MS cases
relative to controls (q = 0.03). Our study provides a detailed map
of MS risk loci that function by regulating gene expression in cell
types relevant to MS.
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Introduction
Multiple Sclerosis (MS) is an autoimmune disease causing multi-
focal central nervous system inflammatory demyelination and
axonal injury. The etiology of MS is unknown, but current evidence
suggests that complex interactions between environmental risk
factors and common genetic variants determine MS susceptibility
(reviewed in Olsson et al [2017]).
Support for a genetic contribution to MS is largely derived from
epidemiological studies that show an association between ancestry
and MS prevalence, and evidence for familial clustering (Ebers et al,
1986; Sadovnick & Baird, 1988; Pugliatti et al, 2001; Baranzini &
Oksenberg, 2017). Linkage studies of families with multiple affected
members with MS show that variation within the human leukocyte
antigen (HLA) class II locus on chromosome 6p21 is associated with
an increased risk of MS, with the main risk allele, HLA-DRB1*15:01,
carrying an average odds ratio of 3.08 (Bertrams & Kuwert, 1976;
Hollenbach & Oksenberg, 2015). More recent genome-wide asso-
ciation studies have identified at least 200 single nucleotide
polymorphisms (SNPs) outside of the MHC region that are asso-
ciated with MS risk (International Multiple Sclerosis Genetics
Consortium et al 2011, 2013, 2019; ). These SNPs are all common
(>2.1% risk allele frequency), are also present in unaffected indi-
viduals, and have small odds ratios of between 0.8 and 1.3, rep-
resenting both protective and risk variants. Hence, carriage of these
common genetic variants is unlikely to be sufficient or necessary for
the pathogenesis of disease.
Importantly, these non-HLA MS risk variants are mainly found
in intronic or intragenic regions, and so their functional effects
are largely unknown (International Multiple Sclerosis Genetics
Consortium et al, 2013). It is recognized, however, that common
noncoding variants associated with traits and diseases, in-
cluding MS, are enriched within DNAse I hypersensitivity sites
and other marks that signify the presence of regulatory DNA,
including promoter and enhancer regions (Maurano et al, 2012;
Elangovan et al, 2014). Genetic loci associated with differential
gene expression are referred to as expression quantitative trait
loci (eQTL), with those acting locally termed cis-eQTL and those
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acting at a distance referred to as trans-eQTL. AsmanyMS risk SNPs are
located near immune-associated genes, some of these could alter
immune gene expression and contribute to immune heterogeneity
(International Multiple Sclerosis Genetics Consortium, 2011). In a piv-
otal study byRaj et al (2014), purifiedmonocyte andCD4-positive T cells
from healthy individuals were used to conduct eQTL mapping of
several candidate SNPs associated with the risk of neurodegenerative
and autoimmune diseases, including MS. In their study, it was dem-
onstrated that disease risk–associated cis-eQTLs were more com-
monly cell type specific compared with non-disease–associated cis-
eQTLs and that MS risk–associated cis-eQTLs were overrepresented in
CD4 T cells. The authors, therefore, suggested that genetic regulation in
CD4 T cells could determine the immune contribution to MS risk.
Although eQTL mapping studies using cells from healthy indi-
viduals have greatly extended our knowledge of the likely functions of MS
risk SNPs and their contributions to immune heterogeneity, there is now
emerging evidence that regulatory variants cangainor lose their influence
on transcriptional regulation in response to pro-inflammatory cytokine
stimulation and other acquired cell states (Fairfax et al, 2012; Kim et al,
2014; Lee et al, 2014; De Jager et al, 2015). Hence, there is a clear need to
consider the effects of disease risk variants both in the context of cell type
and disease status. In the current study, we comprehensively investigated
transcriptional changes associated with MS risk SNPs in recirculating
leukocytes. We evaluated the effects on gene expression in purified
immune cell types from both untreated MS cases and healthy controls.
Results
Patient demographics and sample acquisition
A total of 73 MS cases and 97 unaffected controls were included in
the analysis, and their demographics are summarized in Table 1. Of
the 73 cases, 3 were classed as clinically isolated syndrome (2/3
have since converted to relapsing-remitting multiple sclerosis), two
progressive relapsing, and 64 relapsing-remitting multiple scle-
rosis. Note that no clinical data were available for two cases.
Five types of immune cells were investigated: monocytes, NK cells, B
cells, CD4 cells, and CD8 cells. Not all cell types were analysed for all
individuals. The number of available datasets for each cell type was
determined by blood volumes collected, individual cell yields, and cell
purity (Table 1).
Cis-eQTL associations for MS cases and unaffected controls
Each cell type was analysed separately. In our initial studies, we
combined case and control datasets for each cell type to search for
cis eQTL associations between 172 non-MHC MS risk SNPs (some
correlated with each other) and 1,538 genes with transcription start
sites within ±500 kb of a risk SNP. We analysed 2,711 SNP–gene pairs
in each cell type, modeling log expression as a linear function of
number of MS risk alleles carried (0, 1, or 2) and adjusting for
case–control status. The associations with false discovery rate
(FDR) q < 0.05 are listed in Supplemental Data 1 for each cell type.
The numbers of genes per cell type varied from 33 in NK cells to 57 in
CD8 T cells. In total, the list comprises 129 genes, including 53 genes
whose expression is associated with MS risk genotype in more than
one cell type (Fig 1). For all but 4 of these 53 genes, the directions of
association were the same across cell types; for three of the four
exceptions (MANBA, ADCY3, and JAZF1), the direction of association
differed between monocytes and other cell types. Gene expression
associations were identified for 100 of the 172 SNPs. We testedmany
pairs of SNPs in LD with one another; grouping SNPs in LD r2 > 0.5
together leaves 128 groups of SNPs (Supplemental Data 2), of which
68 groups were eQTLs in at least one cell type (Table 2).
The MS risk SNPs were genotyped using Illumina’s Immunochip
custom array, which includes assays for many other SNPs near MS risk
SNPs. For 42% (136/321) of the MS risk SNP–gene pairs identified with q <
0.05 across the five cell types, the MS risk SNP was the most significant
eQTL on the Immunochip for that gene, or in strong linkage disequi-
librium (r2 > 0.8) with the most significant eQTL for the gene. In other
cases, we adjusted associations between the MS risk SNP and the gene
for genotypes at the most significant eQTL. In 28% of cases (89/321), the
coefficient of theMS risk SNPwas reducedbymore than 70%, or changed
sign. For the remaining30%of cases (96/321), the coefficientof theMS risk
SNP was reduced by less than 70% (Supplemental Data 3). Data for
individual MS risk SNP–gene pairs are presented in Supplemental Data 4.
For each cell type, the top ranked association with an MS risk SNP
is graphically represented in Fig 2A–E. Gene pathway analysis was
performed based on lists of associated genes for each cell type,
using Ingenuity Pathway Analysis software (QIAGEN Inc., https://
www.qiagenbioinformatics.com/products/ingenuity-pathway-
analysis). Genes in a few canonical pathways were enriched among
the lists of top-ranked genes for each cell type, but the number of
genes within these pathways was relatively small and, hence,
provided limited functional insight (Supplemental Data 5).
Effects of disease status on eQTLs
Among these cis eQTLs, there are a few with differences in ex-
pression between cases and controls. Expression of TUBD1 in NK
cells was 7.7% higher in cases than controls after adjustment for
genotype at rs180515 (P = 0.001, FDR q = 0.05 after adjusting formultiple
testing of 45 SNP–gene pairs in NK cells) (Fig 3A). For two of the
strongest eQTLs, there is evidence of genotype–phenotype interaction,
where the eQTL effect differs between cases and controls. The rs703842
Table 1. Multiple Sclerosis case and healthy control demographics and
sample numbers.
Measure Case Control
Total (n) 73 97
Female:male ratio 2.8:1 1.9:1
Median age (yr; range) 39.2 (20–65) 36.2 (21–64)
Median disease duration (yr; range) 7 (0.1–36) —
Median EDSS (range) 2.0 (0–6.0) —
Sample numbers for monocyte cells 53 78
Sample numbers for NK cells 45 78
Sample numbers for B cells 37 87
Sample numbers for CD4 cells 38 85
Sample numbers for CD8 cells 55 91
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MS risk allele (A) is associated with lower expression of the
methyltransferase-like 21B (METTL21B) gene in CD8 cells of both cases
and controls. However, the effect is stronger in cases (P = 0.0003 for
genotype–phenotype interaction, FDR q = 0.03 after adjustment for
multiple testing of 83 SNP–gene pairs in CD8 cells). In particular, cases
that are homozygous for the risk allele have lower expression of
METTL21B relative to controls of the same genotype (Fig 2F). Similarly,
the rs2760524 risk allele (G) is associated with lower expression of the
regulator of G protein signaling 1 (RGS1) gene in monocytes of both MS
cases and healthy controls; however, the effect of this allele is smaller
Figure 1. A graphical representation of expression quantitative trait loci genes by cell type.
This Venn diagram depicts the genes (gene symbol given) associated with one or moremultiple sclerosis (MS) risk single-nucleotide polymorphisms, per cell type. Here,
we identify both cell type–specific and shared expression quantitative trait loci in each of the cell types assayed. Genes where the MS risk allele is associated with higher
expression are colored brown, genes with the MS risk allele is associated with lower expression are colored blue, and genes where the direction of expression change
varies between cell types are underlined.
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in MS cases (P = 0.002 for genotype–phenotype interaction, FDR q = 0.1
after adjustment for multiple testing of 71 SNP–gene pairs in mono-
cytes, Fig 2A). Table 3 shows all other SNP–gene pairs among the eQTLs
with evidence of genotype–phenotype interaction (unadjusted P <
0.05). Interestingly, two candidate SNPs that were not identified as
eQTL in additive linear models using the combined case and control
dataset were found to have significant genotype by phenotype in-
teraction terms. The rs2256814 MS risk allele (A) appeared to have
opposing effects on gene expression in CD4 cells of MS case relative to
controls, associated with lower expression of the Myelin transcription
factor 1 (MYT1) gene in MS cases (q = 0.05, adjusted for 2,711 pairs) (Fig
3B). Similarly, the rs12087340 MS risk allele (A) was associated with
lower expression of the RF00136 gene in monocytes of MS cases and
higher expression in controls (q = 0.04) (Fig 3C).
Comparisons of expression between cases and controls
In addition to analyses incorporating genotypes at MS risk SNPs, we
also ran simple tests of differential expression between cases and
controls. Among all genes within 500 kb of MS risk SNPs, expression
of SOCS1 in B cells was 16% higher in cases than controls (P = 2 ×
10−5, FDR q = 0.03 after adjustment for testing 1,538 genes near MS
risk SNPs; Fig 3D). After correction for multiple testing, there were no
other significant differences for genes near MS risk SNPs. Searching
all transcripts represented on the microarray chip, expression of
SESN1 in B cells was 41% higher in cases than controls (P = 4 × 10−8,
FDR q = 0.001 after adjustment for testing 33,297 genes, Fig 3E) and
expression of FKBP5 in CD4 T cells was 22% higher in cases than
controls (P = 2 × 10−8, FDR q = 0.0007, Fig 3F). Full results of the
case–control comparisons are shown in Supplemental Data 6.
Discussion
Our comprehensive eQTL mapping studies reveal a significant
contribution of MS susceptibility loci to genetically determined
immune heterogeneity. Here, we describe eQTL associations for 129
genes in one or more immune cell types. For most of these genes,
expression is influenced by multiple cis eQTLs, not just MS risk
SNPs. Furthermore, for some of the associations we report, it is
unlikely that MS susceptibility alleles influence gene expression
directly, particularly when the association is substantially reduced
after adjusting for genotypes at a nearby, stronger eQTL.
Interestingly, in contrast to previous reports by Raj et al (2014),
we did not find evidence for a predominance of CD4 T-cell–specific MS
risk eQTL associations within our studied population of MS cases and
controls. Although Fig 2 probably overrepresents the number of cell-
type–specific eQTLs because of the imposition of a fixed significance
threshold, it nevertheless suggests that cell-type–specific eQTLs are
relatively evenly distributed across innate and adaptive immune cell
types. Based on these observations, we, therefore, propose that both
the innate and adaptive arms of the immune system are likely to be
important in determining individual susceptibility to MS.
Using multivariable linear regression models, we provide pre-
liminary evidence that a small number of MS risk variants have dif-
ferential effects on gene expression in MS cases compared with healthy
controls. This is in line with recent observations by James et al (2018),
who used monocytes isolated from healthy controls to show that some
MS risk SNPs exert differential effects on gene expression after stim-
ulation of these cells with interferon-γ or lipopolysaccharide. The
context-specific nature of some eQTLs has also been demonstrated
morewidely both in vitro (Fairfax et al, 2014; Hu et al, 2014; Kim et al, 2014;
Lee et al, 2014) and in vivo (Peters et al, 2016). Earlier eQTL mapping
studies of disease risk loci were restricted to cells from healthy indi-
viduals (e.g., Raj et al [2014]) and, thus, could not assess if MS risk eQTL
can be modified by disease-associated factors. Here, we describe at
least one MS risk eQTL association, with a differential effect size in MS
cases relative to controls. In CD8 cells, we show that rs703842 risk allele is
associated with lowerMETTL21B expression in cases relative to controls.
It has been reported that the encoded METTL21B protein functions as a
methyltransferase, catalysingmethylation on lysine 165 of the eukaryotic
elongation factor 1A (eEF1A) (Hamey et al, 2017; Matecki et al, 2017). The
eEF1A protein is a subunit of the eEF1A translation complex, which is
responsible for the enzymatic delivery of aminoacyl tRNAs to the ri-
bosome and is, thus, ubiquitously expressed in the context of protein
synthesis. METTL21B is also reported to have roles in actin organization,
apoptosis, the nuclear export of tRNAs, the guidance of damaged or
misfolded proteins to the proteasome, viral propagation, microRNA
biogenesis, and RNA interference (Reviewed in: Sasikumar et al [2012]
and Yi et al [2015]). Hence, reduced expression of METTL21B gene ex-
pression in CD8 cells of MS cases could potentially affect a wide range of
molecular pathways in these cells.
We also report two associations, rs2256814 MYT1 in CD4 cells and
rs12087340 RF00136 in monocyte cells, with opposing effects on
gene expression in MS cases compared with controls. Interestingly,
these associations were not detectable where log expression was
Table 2. Summary of the number of reported expression quantitative trait loci associations by cell type.
Cell type Total eQTL associations reported(SNP–gene pairs)a
No. of LD
groupsb
No. of individual
genesc
No. of cell-specific LD
groupsb
No. of cell-specific
genesc
Monocytes 71 37 44 6 17
NK cells 45 27 33 1 11
B cells 54 27 42 1 15
CD4 cells 68 44 51 9 15
CD8 cells 83 41 57 4 18
aThe SNP–gene pairs are listed in Supplemental Data 3.
bThe LD groups are listed in Supplemental Data 2.
cThe genes are listed in Supplemental Data 1 and Fig 1.
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simply modeled as a linear function of the number of MS risk alleles
carried in the combined case and control dataset, likely because of
the variance produced by these differential regulatory effects. Little
is known about the functions of the small nucleolar RNA encoded
by RF00136; however, MYT1 protein is a known transcription factor that
has been shown to bind the promoter region of themyelin proteolipid
protein gene (Kim & Hudson, 1992). The MYT transcription factor has
been reported to play a role in oligodendrocyte development and
possibly remyelination (Nielsen et al, 2004; Vana et al, 2007), but may
also have wider functions in neural cell development (Yokoyama et al,
2014). The expression of MYT1 is widely reported as being restricted to
adult neural cells; however, Vana et al (2007) did report MYT1 protein
expression in some infiltrating lymphocytes in MS lesional tissue.
Although the functions of the MYT1 protein in lymphocyte cells remain
unknown, the observed association between the rs2256814MS risk SNP
genotype and MYT1 gene expression in CD4 cells in our dataset raises
Figure 2. The top ranked expression quantitative trait loci (eQTL) associations.
Graphical representation of the top ranked eQTL associations at non-human leukocyte antigen multiple sclerosis (MS) risk loci, for each immune cell type, sorted by false
discovery rate. For each eQTL association, log2 gene transcript expression is shown for MS cases and healthy controls, segregated by single-nucleotide polymorphism (SNP)
genotype. The regression lines in each figure demonstrate the associations between genotype and gene expression for each SNP/gene pair. Associations for controls (solid
green lines) are superimposed on case plots (dashed purple lines) to facilitate comparison with case associations (solid purple lines). (A) In figure (A) the regulator of G-
protein signaling 1 (RGS1) transcript log2 expression versus rs2760524 genotype is shown formonocyte cells (risk genotype = G; q = 2 × 10−47). Interestingly, there also appears to
be a difference in the effect size of genotype on RGS1 gene expression, betweenMS cases and controls: each additional copy of theG allele is associatedwith a 56% reduction of
expression in controls, but only a 40% reduction of expression in cases (q = 0.1 for difference). (B) In figure (B), the Gasdermin B (GSDMB) log2 transcript expression versus
rs12946510 (risk genotype = A; q = 2 × 10−36) genotype is shown for NK cells. (C, D, E) The Abelson helper integration site 1 (AHI1) log2 transcript expression versus rs1115480
genotype 1 (risk genotype = A; q = 3 × 10−72) is shown for MS cases and controls in B cells (C), CD8 cells (q = 3 × 10−71) (D), and CD4 cells (q = 6 × 10−77) (E). (F) In (F) graphing the
association between rs703842 genotype (risk genotype = A) and METTL21B log2 transcript expression in CD8 cells, it reveals a difference in effect of the risk allele on gene
transcript expression in MS cases relative to controls (genotype-by-phenotype interaction q = 0.03 adjusted for 83 eQTL SNP/gene pairs).
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the intriguing possibility that this SNP could regulate MYT1 gene ex-
pression in neural cells of MS cases in a similar way.
Interestingly, after adjustment for the SNP genotype, only one eQTL
gene was found to be differentially expressed in MS cases relative to
controls, TUBD1 inNK cells. Hence, ourfindings suggest that these genes
may not contribute to the disease process itself. Our transcriptome-
wide analyses, without adjustment for genetic effects, identified only a
few genes that were clearly differentially expressed in immune cells of
theMS cases versus controls. Our data suggest that the functional state
of immune cells isolated from peripheral blood, in this population of
untreatedMS cases with relatively early and stable disease, is similar to
that of healthy controls. Two caveats are that potentially causative
molecular variation is probably only present in a small subset of all
cells of a specific population (e.g., CD4 T cells) and that thesemaynot be
detectable in the peripheral blood compartment. Our experimental
design was enriched for eQTL associations detectable in the resting
immune state in MS cases and healthy controls. Considering the
emerging evidence for context-dependent activity at some genetic loci,
additional detailed eQTL mapping studies using more refined immune
cell subsets or using cells isolated during acute inflammatory relapse,
or from lymph nodes, efferent lymph or CSF, could reveal regulation of
gene expression in risk loci that were not captured using our experi-
mental design. It is also possible that we may have missed some
specific SNP transcriptional effects such as splicing and noncoding RNA
using this microarray based approach.
Because of limited sample sizes and complexities associated
with multiple testing, we acknowledge that our novel observations
must be independently validated. However, we suggest that the
overall signal of differential regulatory effects in MS cases com-
pared with unaffected controls is likely to be robust, even if some of
the individual signals may not be replicated. It also remains unclear
how the functions of these risk variants are regulated in MS cases to
produce these disease specific patterns of expression, if these
disease associated differences in eQTL effect size are a cause or
consequence of disease onset, or if they contribute to an abnormal
immune response. Our results confirm, however, that there is a
genetic contribution to immune heterogeneity in MS cases that is
conveyed by MS risk SNPs and is detectable in the absence of overt
immune activation. It is hoped that these studies will inspire a more
concerted effort to capture genetically determined immune variation
in the context of complex human disease, taking advantage of de-
veloping technologies to increase sensitivity and specificity.
Materials and Methods
Study population and approvals
Our study population included MS cases recruited from Box Hill
Hospital, Victoria, between 2009 and 2013. Diagnoses were made by
MS neurologists according to the McDonald (2001) criteria. Cases
were not relapsing at the time of sample collection and were not
treated with disease-modifying drugs or immunosuppressants for at
Table 3. Expression quantitative trait loci with some evidence of genotype–phenotype interaction.
Cell type SNP Gene Genotype q-value Genotype × phenotype P-value
Monocytes rs2760524 RGS1 2 × 10−47 2 × 10−3
Monocytes rs1323292 RGS1 2 × 10−47 2 × 10−3
Monocytes rs1359062 RGS1 6 × 10−45 1 × 10−2
Monocytes rs533646 RNU6-376P 8 × 10−5 3 × 10−2
Monocytes rs4665719 ADCY3 1 × 10−2 5 × 10−2
Monocytes rs11052877 CLECL1 5 × 10−4 5 × 10−2
NK cells rs4648356 TNFRSF14 1 × 10−2 3 × 10−2
B cells rs12946510 ORMDL3 1 × 10−20 7 × 10−3
B cells rs12946510 GSDMB 4 × 10−17 2 × 10−2
B cells rs180515 TUBD1 4 × 10−3 3 × 10−2
CD4 cells rs1021156 PKIA 1 × 10−6 8 × 10−3
CD4 cells rs2288904 SLC44A2 1 × 10−5 2 × 10−2
CD4 cells rs703842 METTL21B 4 × 10−22 3 × 10−2
CD4 cells rs12212193 BACH2 2 × 10−3 4 × 10−2
CD4 cells rs201202118 METTL21B 7 × 10−27 4 × 10−2
CD8 cells rs703842 METTL21B 3 × 10−40 3 × 10−4
CD8 cells rs201202118 METTL21B 1 × 10−47 1 × 10−3
CD8 cells rs9989735 SP140 5 × 10−2 8 × 10−3
CD8 cells rs941816 ETV7 2 × 10−4 2 × 10−2
CD8 cells rs949143 ARL6IP4 3 × 10−3 3 × 10−2
SNP–gene pairs with an unadjusted genotype by phenotype P-value less than 0.05 are shown.
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least 1 mo before participating in the study. Unaffected controls were
generally allied health staff, nurses, research scientists, and spouses/
partners of MS patients, who had no known neurological or
autoimmune diseases. The age and gender of unaffected controls
were also recorded. All MS and healthy control participants were
selected for European ancestry, to minimize confounding by ancestry
and because most Australian patients with MS are of European an-
cestry. The case and control demographics are summarized in Table 1.
The study was conducted according to the Declaration of Hel-
sinki principles and was approved by the Human Research Ethics
Figure 3. Multiple sclerosis (MS) case and control differences in gene expression.
(A) In (A) the expression of tubulin delta 1 (TUBD1) in NK cells is higher in MS cases relative to controls after adjustment for rs180515 genotype (risk allele G; q = 0.05 adjusting
for 45 expression quantitative trait loci associations). (B) The rs2256814 risk allele A is associated with lower expression of the myelin transcription factor 1 (MYT1) gene in MS
cases and higher expression in controls (genotype-by-phenotype interaction q = 0.05 adjusted for 2,711 pairs). (C) Similarly, the rs12087340 risk allele A is associated with lower
expression of theRF00136 gene inMS cases and higher expression in controls (q = 0.04 adjusted for 2,711 pairs). (D, E, F) The SOCS1 gene in B cells, localized to themiddle of a
cluster ofMS risk single-nucleotide polymorphisms on chromosome 16, (E) SESN1 in B cells, and (F) FKBP5 in CD4 T cells. In (A, B, C), the regression lines for controls (solid green
lines) are superimposed on case plots (dashed purple lines) to facilitate comparison with case associations (solid purple lines). In (D, E, F), themean log2 expression values for
controls (solid green lines) are superimposed on case plots (dashed purple lines) to facilitate comparison with case means (solid purple lines).
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Committees from the participating hospital. Written informed
consent was obtained from all participants.
Isolation of circulating peripheral immune cells and RNA
preparation
A venous blood sample of up to 110 ml was collected into EDTA-
coated blood collection tubes (Becton Dickinson), from each par-
ticipant between 7:30 AM and 11:00 AM, to minimize the influence of
circadian variation. For isolation of PBMCs, B cells, and CD4 and CD8 T
cells, up to 70 ml of blood was diluted twofold with PBS (dPBS, 2 mM
EDTA, and 2% FCS) and slowly layered on to 15 ml Histopaque-1077 in
50-ml tubes (Sigma-Aldrich). The samples were centrifuged at 400g
(brakes off) for 30min at room temperature and then the PBMC layer
was removed using a glass pipette. The cells were washed twice with
PBS solution, counted, and incubated with human CD19, and CD8
microbeads for on-column (LS) positive selection of B cells and CD8 T
cells, respectively, according to the manufacturers’ instructions
(Miltenyi Biotech). The negative fractions from the CD8 cell sepa-
ration were used to isolate CD4 T cells by magnetic cell sorting using
CD4 microbeads (Miltenyi Biotech), according to the manufacturer’s
instructions. For isolation of monocytes and NK cells, 40 ml of blood
was centrifuged at 400g (brakes off) for 15 min at room temperature,
and the buffy coat layer was removed using a glass pipette. The buffy
coat was then divided into two portions for incubation with
RosetteSep human monocyte and NK cell enrichment cocktails
(Stemcell Technologies), respectively. Each portion was then layered
on to 5 ml Histopaque in 15-ml tubes, centrifuged at 1,200g (brakes
off), and the enriched cell layers were removed using a glass pipette.
The cells were washed, counted, and labelled with human CD14
(monocytes) or CD56 (NK cells) microbeads for positive cell selection
using an autoMACS Pro separator (Miltenyi Biotech). After isolation,
purity was checked using standard flow cytometry protocols on a
Cyan Flow cytometer (Beckman Coulter), and only samples that were
>90% pure were included. We isolated immune cell type RNA using
RNeasy mini kits (QIAGEN), and the RNA yield was quantified
spectrophotometrically on a NanoDropND-1000.
Microarray processing
Using 100 ng of RNA/sample, expression microarray hybridizations
were performed using the WT Expression kit (Life Technologies), WT
Terminal Labelling and Controls Kit (Affymetrix), and Affymetrix Human
Gene_1.0ST arrays, which contain 764,885 distinct probes. The probed
arrays were washed and stained using the GeneChip Hybridization
Wash and Stain Kit (Affymetrix) and scanned using the GeneChip
Scanner 3000. Images (.dat files) were processed using GeneChip
Command Console (Affymetrix) and CEL files imported into Partek
Genomics Suite 6.6 (Partek SG) for further quality control checks.
Genotyping
WholebloodgenomicDNAwas isolatedusing the IllustraNucleonBACC3
kit according to the manufacturer’s instructions. All MS cases and un-
affected controls were genotyped using the Immunochip custom array
(Illumina) in accordance with Illumina protocols, at the University of
Queensland Diamantina Institute (Brisbane, Australia). Genotype calling
was performed using lllumina iScan System and the GenotypingModule
(v.1.8.4) of the GenomeStudio Data Analysis software.
Genotyping quality control
PLINK was used to perform linkage disequilibrium-based SNP
pruning and to estimate pairwise identity-by-descent between
individuals using the pruned SNP set (Purcell et al, 2007). Four close
relative pairs were identified (second-degree relatives or closer),
and one individual from each relative pair was removed from the
dataset. In a principal components analysis of the pruned geno-
types, there were no outlier samples more than six SDs from the
mean along the first 10 principal components. Testing for differ-
ences in allele frequencies between MS cases and controls, the
estimated genomic inflation factor (λ) was 0.9986.
Selection of MS risk SNPs to test for association with gene
expression
A total of 183 SNPs outside the MHC region, previously identified in
large-scale genome wide association studies as significantly or
strongly suggestive of being associated with MS risk (International
Multiple Sclerosis Genetics Consortium et al 2011, 2013; Patsopoulos
et al, 2011), were considered for testing as candidate eQTLs (see
Supplemental Data 2 for a list of these SNPs). 16 of the 183 SNPs were
not included in eQTL analyses: 12 because they were not on the
Immunochip and 4 because genotypes were called in less than 95%
of samples. For these 16 SNPs, the LDlink Web site was used to search
for proxies on the Immunochip using 1000 Genomes Data from
European populations (Machiela & Chanock, 2015). For 3 of the 16
excluded SNPs, the best proxy was an SNP already included in the list
of MS risk SNPs. For another five SNPs, additional proxies were
identified (r2 between 0.59 and 1.00) and included in the analysis. For
the remaining eight excluded SNPs, no proxy (r2 > 0.5) was found on
the Immunochip. Hence, analyses included 172 SNPs: 167 of the
original 183 MS risk SNPs plus five additional proxy SNPs. Genotype
call rates were greater than 98%, andHardy–Weinberg equilibrium P-
values were greater than 0.002 for all 172 SNPs. These SNPs cluster
into 128 LD groups, with r2 > 0.5 between SNPs in the same LD group
(Supplemental Data 2).
Processing and analysis of expression data
Expression datasets for each cell type were analysed separately
throughout.
Expression measurements for samples of each cell type were
preprocessed using the Robust Multi-array Average algorithm as
implemented in the R package “oligo” (Carvalho & Irizarry, 2010), to
perform background correction, quantile normalization, and to
summarize expression at the “core gene” level (33,297 genes) for
each sample.
The R package “Remove Unwanted Variation” (RUV) was used to
test for associations between genotype, phenotype (MS case or
control), and expression (Gagnon-Bartsch & Speed, 2012; Gagnon-
Bartsch et al, 2013). Methods from this package use negative control
genes to estimate factors of unwanted variation W. Then log gene
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expression values Y are modeled as functions of W and factors of
interest X:
Y = Xβ + Wα + ε:
A set of 575 housekeeping genes, mapping to 593 Affymetrix
cluster IDs, was used as negative controls (Eisenberg & Levanon, 2003).
RUV includes several methods to estimate factors of unwanted variation
W from negative controls, including methods called RUV-2, RUV-4, RUV-
inv, and RUV-rinv. Performances of these methods were compared by
applying them to our monocyte dataset and measuring the rates of
detection of 193 “high confidence eQTLs” identified in two previous
monocyte eQTL studies with associated SNPs on the Immunochip (Zeller
et al, 2010; Fairfax et al, 2012; Yu et al, 2016). In the end, we settled on the
ridged inversemethod (RUV-rinv)with empirical variance estimates for all
differential expression analyses. There were several reasons for choosing
this method: diagnostic plots, the method’s ability to detect high confi-
dence monocyte eQTLs, its insensitivity to choice of negative controls
(compared with RUV-2), and the advantage that it does not require es-
timationof thenumber of unwanted factors (unlikeRUV-2 andRUV-4). For
each of the five cell types and each of the 172 MS-associated SNPs, two
RUV-rinv models were run: one with X comprising two factors of interest
(number ofMS risk allelesG and phenotype P) and onewith X comprising
three factors (G, P, and genotype-by-phenotype interaction G × P).
In addition to these eQTL analyses, a simple case–control
comparison was run using RUV-rinv for each cell type, that is, with
phenotype the only factor of interest (X = P).
Significance thresholds to allow for multiple testing
To search for cis eQTLs, we examined coefficients of genotype G in
the two-factor models for genes whose transcription start sites
lie within 500 kilobases of the 172 MS-associated SNPs (hg38
genome build). The FDR method of Benjamini and Hochberg was
used to adjust for multiple testing of the 2,711 SNP–gene pairs
that were identified. The same adjustment was applied to search
the 2,711 SNP–gene pairs for associations with phenotype in the
two-factor models, and for genotype–phenotype interactions in
the three-factor models. We also looked for phenotype and in-
teraction effects just among the cis eQTLs, applying a less
stringent adjustment controlling for the number of eQTLs
identified in each cell type.
For each gene whose expression was associated with genotypes
at an MS risk SNP with FDR q < 0.05, we searched for other eQTLs
within 500 kb of the transcription site of the gene. For each SNP on
the Immunochip within this distance, the same RUV-rinv models
were run as for the MS risk SNP. The SNP showing the most sig-
nificant association with the gene was recorded and linkage dis-
equilibrium calculated between this SNP and the MS risk SNP. For
genes where r2 between genotype Gsig at the most significant SNP
and genotype GMS at the MS risk SNP was less than 0.8, we ran an
RUV-rinv model with genotypes at both SNPs included:
Y = GMSβMS-adj + Gsigβsig + PβP + Wα + ε:
This calculates the effect βMS-adj of the MS risk SNP on log gene
expression adjusted for genotypes at the most significant SNP. This
coefficient was compared with the unadjusted coefficient βMS-unadj
estimated from the original RUV-rinv model:
Y = GMSβMS-unadj + PβP + Wα + ε:
To search for genes differentially expressed between MS cases
and controls without consideration of genotypes, we searched both
among the 1,538 genes within 500 kb of the 172 MS-associated SNPs
and transcriptome wide, applying appropriate FDR corrections in
the two cases.
The R package “venn” (Dusa, 2018) was used to plot a Venn
diagram showing which genes’ expression levels were associated
with MS risk SNPs in which cell types.
Cross-normalization
Expression levels were plotted for selected SNP–gene pairs to show
genotype, phenotype, and genotype-by-phenotype effects after removal
of unwanted variation. Estimating and subtracting the term Wα for un-
wanted variation results in over-adjustment (data not shown). A simple
variant of this strategy, called cross-normalization, is very effective (Y Pan
and J Gagnon-Bartsch, manuscript in preparation). As in cross-validation,
cross-normalization omits eachobservation (here case or control sample)
in turn and estimates the quantities needed for removing the unwanted
variation from that omitted observation, using all the other observations.
Cross-normalized expression valueswere calculated by applying RUV-rinv
with design matrix X = [G|P|G × P] or X = P and were plotted using the R
package “beeswarm” (Eklund, 2016). Cross-normalization with X = P was
used to calculate adjusted expression values for making relative log
expression and singular value decomposition plots. Comparison of these
plots before and after cross-normalization demonstrated the presence
and removalofbatcheffects in theexpressiondata (SupplementalData 7).
Pathway analyses
Gene ontology and biological pathway analyses were conducted
using Ingenuity Pathway Analysis Software (QIAGEN Inc., https://
www.qiagenbioinformatics.com/products/ingenuity-pathway-
analysis) using lists of genes whose expression was significantly
associated with MS risk SNPs in each cell. These analyses were not
performed for transcriptome-wide case versus control compari-
sons, as relatively few genes were within the FDR cutoff of <0.05.
Data Availability
TheCELfiles, RobustMulti-arrayAverage-adjustedgeneexpressionvalues
for all tested transcripts, and SNP genotype data generated in this study
have been deposited at the European Genome-phenome Archive (EGA),
which is hosted by the European Bioinformatics Institute and the Centre
for Genomic Regulation, under accession number EGAS00001004087.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
202000650.
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